FFM
Fairmount Funds Management Portfolio holdings
AUM
$772M
This Quarter Return
+45.82%
1 Year Return
+35.05%
3 Year Return
+1,168.51%
5 Year Return
+1,432.11%
10 Year Return
–
AUM
$946M
AUM Growth
+$946M
(+14%)
Cap. Flow
-$120M
Cap. Flow
% of AUM
-12.66%
Top 10 Holdings %
Top 10 Hldgs %
89.29%
Holding
20
New
–
Increased
5
Reduced
2
Closed
4
Top Buys
| 1 |
Astria Therapeutics
ATXS
|
$12.7M |
| 2 |
argenx
ARGX
|
$11.1M |
| 3 |
Kiniksa Pharmaceuticals
KNSA
|
$7.17M |
| 4 |
Axsome Therapeutics
AXSM
|
$1.5M |
| 5 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$1.49M |
Top Sells
| 1 |
Nuvalent
NUVL
|
$38.8M |
| 2 |
Soleno Therapeutics
SLNO
|
$33.7M |
| 3 |
Merus
MRUS
|
$32M |
| 4 |
Immunovant
IMVT
|
$28.8M |
| 5 |
Trevi Therapeutics
TRVI
|
$11.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Axsome Therapeutics
AXSM
$6.05B
| $188M | 19.85% | 2,360,077 +18,839 | +0.8% | +$1.5M |
|
|
IMGN
2
DELISTED
Immunogen Inc
IMGN
| $176M | 18.58% | 5,929,592 | – | – |
|
|
3
Nuvalent
NUVL
$5.52B
| $142M | 14.96% | 1,924,626 -527,193 | -22% | -$38.8M |
|
4
Apogee Therapeutics
APGE
$2.17B
| $82.2M | 8.68% | 2,941,176 | – | – |
|
|
RYZB
5
DELISTED
RayzeBio, Inc. Common Stock
RYZB
| $77.5M | 8.18% | 1,245,929 +24,025 | +2% | +$1.49M |
|
|
6
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $50.6M | 5.34% | 2,883,221 +408,660 | +17% | +$7.17M |
|
|
7
argenx
ARGX
$43.6B
| $43M | 4.54% | 112,903 +29,156 | +35% | +$11.1M |
|
8
Viridian Therapeutics
VRDN
$1.5B
| $29.8M | 3.15% | 1,369,623 | – | – |
|
9
Enliven Therapeutics
ELVN
$1.2B
| $29.5M | 3.12% | 2,131,369 | – | – |
|
|
10
Astria Therapeutics
ATXS
$349M
| $27.3M | 2.88% | 3,554,129 +1,652,732 | +87% | +$12.7M |
|
11
Cogent Biosciences
COGT
$1.69B
| $20.9M | 2.21% | 3,558,975 | – | – |
|
12
Dianthus Therapeutics
DNTH
$759M
| $20.1M | 2.12% | 1,928,503 | – | – |
|
|
13
Merus
MRUS
$4.98B
| $19.7M | 2.08% | 717,254 -1,164,091 | -62% | -$32M |
|
14
Tyra Biosciences
TYRA
$675M
| $19.3M | 2.04% | 1,393,329 | – | – |
|
15
Terns Pharmaceuticals
TERN
$609M
| $13.2M | 1.4% | 2,040,000 | – | – |
|
16
Spyre Therapeutics
SYRE
$996M
| $8.14M | 0.86% | 378,421 | – | – |
|
|
DBVT
17
DBV Technologies
DBVT
$264M
| – | – | -6,781,150 | Closed | -$9.22M |
|
|
18
Immunovant
IMVT
$2.56B
| – | – | -750,000 | Closed | -$28.8M |
|
|
19
Soleno Therapeutics
SLNO
$3.6B
| – | – | -1,142,473 | Closed | -$33.7M |
|
|
20
Trevi Therapeutics
TRVI
$883M
| – | – | -5,163,287 | Closed | -$11.3M |
|